The preliminary clinical study of adrenomedullin therapy in inflammatory bowel disease.
| Project/Area Number |
24790711
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Gastroenterology
|
|---|
| Research Institution | University of Miyazaki |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2015-03-31
|
| Project Status |
Completed (Fiscal Year 2014)
|
| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2013: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | アドレノメデュリン / 炎症性腸疾患 / 潰瘍性大腸炎 / 臨床研究 / トランスレーショナルリサーチ / 粘膜再生 / 生理活性ペプチド / 新規治療薬 |
|---|
| Outline of Final Research Achievements |
Adrenomedullin (AM) is a pluripotent biologically active peptide, and is known to have an anti-inflammatory effect and improve the severity of colitis in experimental colitis models.
In this study, we evaluated the safety and preliminary efficacy of exogenous AM administered to patients with inflammatory bowel disease (IBD) in an open-labeled exploratory trial. AM was administrated intravenously for 8 hours daily for 14 days. Disease activity index (DAI) score including endoscopic findings were evaluated before and after administration of AM (at 2 and 12 weeks). DAI score and serum inflammatory cytokines levels after AM therapy were significantly improved compared with that at baseline. No adverse effect have shown clinically during AM administration. AM is a possible agent for inducing mucosal healing and clinical remission safely in patients with IBD.
|
Report
(4 results)
Research Products
(12 results)
